Abstract
Background
Treatment success of H. pylori eradication therapy has declined worldwide largely because of increased antimicrobial resistance. New therapeutic approaches are needed, especially for countries like Iran, where resistance to commonly used drugs is already widespread and traditional H. pylori therapies produce poor cure rates.
Aim
to review the results of quadruple therapy trials containing bismuth and furazolidone in Iran.
Methods
We searched PubMed, Google scholar as well as the references of all published papers for studies done in Iran, utilizing furazolidone in the treatment of H. pylori infections. The target population was 4 drug studies that utilized a combination of bismuth, furazolidone, amoxicillin, or tetracycline plus a proton pump inhibitor.
Results
Eighteen studies with 22 arms including 1713 subjects were found. The weighted mean cure rate for 14-day studies (6 studies) using 200 mg b.i.d. furazolidone was 80% intention-to-treat (ITT) and 87% per protocol (PP). Studies using 100 mg b.i.d (3 studies) were less effective (weighted mean ITT cure rate = 67%). One small 14 day study with furazolidone 100 mg q.i.d. achieved cure rates of 94.5% ITT and PP.
Conclusions
Although furazolidone-bismuth quadruple therapy proved relatively effective in Iran, furazolidone-containing regimens remain to be optimized. Based on these data and results from China, it appears likely that 14 day therapy containing furazolidone 100 mg t.i.d. or q.i.d. is likely to provide the highest cure rates with lowest side effects; this remains to be experimentally tested. Detailed suggestions for further development of furazolidone-containing regimens are provided.
Keywords: H. pylori, therapy, furazolidone, amoxicillin, tetracycline, proton pump inhibitors, review
Introduction
Furazolidone is a broad spectrum nitrofuran antimicrobial which has primarily been used in humans for the treatment of diarrheal diseases. In the pre-Helicobacter pylori era, furazolidone was successfully used in the treatment of peptic ulcer disease in China [1]. The subsequent discovery that peptic ulcer disease was caused by infection with H. pylori led to the search for effective antimicrobial therapies [2] which included testing of furazolidone and other nitrofurans for H. pylori eradication therapy. Furazolidone proved to be the only successful anti-H. pylori nitrofuran. Furazolidone, when used as a component of the multidrug regimens, particularly in association with bismuth has been shown to be highly effective for H. pylori eradication [3;4]. However, its use is frequently associated with side effects and a reduction in regimen-adherence [5].
The widespread increase in resistance to antibiotics most commonly used for H. pylori therapy (eg, clarithromycin, metronidazole, fluoroquinolones) has resulted in the search for new antimicrobial regimens. H. pylori resistance has remained rare to tetracycline, amoxicillin and furazolidone making them potentially useful in regions where antimicrobial resistance to other commonly used anti-H. pylori antimicrobials has become a problem. However, in many countries tetracycline is no longer available, in part because its low market price has made it unprofitable to manufacture and market.
Prior to 2002 furazolidone’s largest use was in agriculture. In 2002, the United States Food and Drug Administration prohibited the use of all nitrofuran drugs (eg, dimetridazole; ipronidazole; other nitroimidazoles, furazolidone, nitrofurazone, and other nitrofurans) in food-producing animals due to evidence that the nitrofurans could produce carcinogenic residues in animal tissues. This prohibition also included topical use in agriculture and also in aquaculture (fish, shrimp, etc) so even products of bees such as imported honey are currently tested for the presence of nitrofuran antibiotics. This issue resulted in furazolidone becoming unavailable in many western countries. By 1980 furazolidone was considered an outdated clinical drug, in the United States and because the market was small and declining, the single manufacturer stopped production of the drug and voluntarily gave up its FDA approval [6].
China and Iran both experience high H. pylori prevalence and high burdens of H. pylori-related gastric cancer. In both countries, antimicrobial resistance in H. pylori is common and furazolidone is available [7–14]. In China, a 14 day combination of a proton pump inhibitor, a bismuth salt, plus combinations of furazolidone, tetracycline, metronidazole, or amoxicillin have proven reliably effective for H. pylori eradication [3;4]. The widespread use of antibiotics in Iran has also resulted in a high prevalence of antimicrobial resistance among H. pylori isolates, thus making reliable H. pylori eradication therapy difficult [10–12;15–19]. Furazolidone is clinically available in Iran. Accordingly a number of clinical trials have been done using various combinations of anti-H. pylori antimicrobials comprising of this drug. While triple therapies consisting of a proton pump inhibitor, furazolidone, and amoxicillin proved relatively ineffective, the results were considerably improved by the addition of bismuth (eg, 54% with triple furazolidone (100 mg b.i.d) -containing therapy for 14 days vs. 72% with 100 mg furazolidone b.i.d. plus bismuth, and 92% for 200 mg furazolidone b.i.d. plus bismuth [13;20;21].
In Iran, furazolidone is locally available and considered a cost-effective therapy [13;19;22]. As a result, the current recommended first line H. pylori eradication therapy in Iran is a two week course of b.i.d. therapy consisting of furazolidone 200 mg b.i.d., amoxicillin 1 gm, bismuth 240 mg and a PPI [19;22]. Here, we review the experience with furazolidone-bismuth quadruple therapy in Iran based on the concept that the review of these studies will help identify reliably effective treatment strategies for multidrug resistant H. pylori infections in any region.
Methods
We searched PubMed, Google scholar as well as the references of all published papers, and any papers published from Iran utilizing furazolidone in the treatment of H. pylori infections. The target population was 4 drug studies that utilized the combination of bismuth, furazolidone, amoxicillin, or tetracycline. Each paper was obtained, read and the data extracted by MM, BA and DYG. For each study the intention to treat and per protocol results are presented.
Results
Nineteen papers from Iran with 23 arms were identified that described bismuth, PPI, furazolidone-containing quadruple therapies [21;23–40] (Tables 1–3). One study was excluded because the cure rate was tested after two weeks and while the subjects were still receiving PPIs [39] resulting in 18 studies, with 22 arms including a total of 1713 subjects. In these studies the furazolidone doses were 100 mg b.i.d. or q.i.d, and 200 mg b.i.d. Most studies used bismuth citrate 200 or 240 mg b.i.d., amoxicillin 1000 mg b.i.d, furazolidone, and either omeprazole 20 mg once or b.i.d. or pantoprazole 40 mg b.i.d. The studies were grouped in relation to furazolidone dosage, duration and combination of drugs into the following tables: Table-1: bismuth, furazolidone, amoxicillin, PPI quadruple therapies; Table-2: bismuth, furazolidone, tetracycline, PPI quadruple therapy; Table-3: novel sequential therapies containing bismuth, the PPI, and amoxicillin was give for 10 days and either metronidazole or clarithromycin given for the first 5 days and 200 mg b.i.d. furazolidone given for the second 5 days.
Table 1.
Year | City | Treatment Protocol | Treatment Success | Assays | Reasons for non-compliance | Ref | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bismuth (BPC) | Furazolidone | Amoxicillin | PPI | Days | ITT | PP% | ||||||||
O/P | Dose | N | % | N | % | |||||||||
2004 | Tehran | 240 b.i.d | 100 b.i.d. | 1000 b.i.d. | O | 20 b.i.d. | 14 | 50 | 72 | 49 | 73.4 | UBT | Side effect (n=1) | [21] |
2009 | Shiraz | 240 b.i.d. | 100 b.i.d. | 1000 b.i.d. | O | 20 b.i.d. | 14 | 69 | 49 | 60 | 56 | UBT | Lost (n=9) | [28] |
2009 | Zaheda n | 200 q.i.d. | 100 b.i.d. | 1000 b.i.d. | O | 20 b.i.d. | 14 | 49 | 85.7 | 49 | 85.7 | stool antigen test | – | 40 |
2007 | Isfahan | 200 b.i.d. | 200 b.i.d. | 1000 b.i.d. | O | 20 b.i.d. | 7 | 78 | 71.8 | 66 | 84.8 | UBT | No UBT (n=12) Poor Adherence (n=1) |
[25] |
2012 | Sari | 240 b.i.d. 14 days | 200 b.i.d. 7 day (1st wk) | 1000 b.i.d. 14 day | p | 40 b.i.d. 14 day | 7 | 36 | 80.6 | 35 | 82.9 | UBT | No UBT (n=1) | [36] |
2012 | Sari | 240 b.i.d. 14days | 200 b.i.d. 7 day (1st wk) | 1000 b.i.d. 14 day | p | 40 b.i.d. 14 day | 7* | 148 | 80.4 | 124 | 89.7 | UBT | No adherence (n=12) No UBT (n=11) |
[37] |
2010 | Yazd | 120 q.i.d. 14 days | 200 b.i.d. 7 day (1st wk) | 1000 b.i.d 14 day. | O | 20 b.i.d. 14 day | 7* | 92 | 79.3 | 82 | 89 | RUT/His tology | Lost (n=8) Side effect (n=2) |
[34] |
2011 | Sari | 240 b.i.d. | 200 b.i.d. 7 day (1st wk) | 1000 b.i.d. | O | 20 b.i.d. | 7* | 80 | 86.3 | 72 | 90.3 | UBT | No UBT (n=4) Side effect (n=1) Poor Adherence (n=3) |
[32] |
2015 | Sari | 200 b.i.d. | 200 b.i.d. | 1000 b.i.d. | O | 20 b.i.d. | 10 | 124 | 83.7 | 104 | 86.6 | UBT | Poor Adherence (n=4) Side effect (n=3) |
[38] |
Furazolidone-Amoxicillin–bismuth quadruple therapy (14 day- treatment studies with 200 mg furazolidone b.i.d) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Year | City | Treatment Protocol | Treatment Success | Assays | Reasons for non-compliance | Ref | ||||||||
Bismuth (BPC) | Furazolidone | Amoxicillin | PPI | Days | ITT | PP% | ||||||||
O/P | Dose | N | % | N | % | |||||||||
2001 | Tehran | 240 b.i.d | 200 b.i.d. | 1000 b.i.d. | O | 20 b.i.d. | 14 | 63 | 84 | 59 | 90 | UBT | Lost (n=2) Side effect (n=11) |
[23] |
2003 | Rasht/Tehran | 240 b.i.d | 200 b.i.d. | 1000 b.i.d. | O | 20 b.i.d. | 14 | 90 | 78.9 | 89 | 78 | UBT | Side effect (n=1) | [26] |
2004 | Tehran | 240 b.i.d | 200 b.i.d. | 1000 b.i.d. | O | 20 b.i.d. | 14 | 50 | 92 | 49 | 93.8 | UBT | Side effect (n=1) | [21] |
2007 | Tehran | 240 b.i.d | 200 b.i.d. | 1000 b.i.d. | O | 20 b.i.d. | 14 | 104 | 83.6 | 84 | 95.2 | UBT | Side effect (n=7) Poor Adherance (n=2) No UBT (n=7) Lost (n=4) |
[24] |
2007 | Isfahan | 200 b.i.d | 200 b.i.d. | 1000 b.i.d. | O | 20 b.i.d. | 14 | 78 | 73.1 | 66 | 82.6 | UBT | No UBT (n=5) Poor Adherance (n=3) |
[25] |
2011 | Qum | 240 b.i.d | 200 b.i.d. | 1000 b.i.d. | O | 20 b.i.d. | 14 | 43 | 67.4 | 34 | 85.3 | UBT | Side effect (n=3) No UBT (n=4) Poor Adherance (n=2) |
[29] |
PPI, proton pump inhibitor; PP, per protocol; q.i.d., four times daily; b.i.d., twice daily; q.i.d., four times daily; q.d. daily; ITT, intention to treat; BPC, bismuth potassium citrate; O, omeprazole; P, pantoprazole.
= sequential type therapy.
Table 3.
Yea r | City | Treatment Protocol | Treatment Success | Assays | Reasons for non-compliance | Ref | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bismuth (BPC) | Furazolidone (mg) plus Other (mg) | Amoxicillin | PPI | Days | ITT | PP% | ||||||||
O/P | Dose | N | % | N | % | |||||||||
2010 | Tehran | 240 b.i.d. | 200 b.i.d. (received metronidazole (M) (500 mg bid) rst 5 days, followed by furazolidone for the second 5 days. | 1000 b.i.d. | O | 20 b.i.d. | 10 | 107 | 78.5 | 92 | 91.3 | UBT | Lost (n=3) Side effect (n=2) No UBT (n=10) |
[30] |
2010 | Tehran | 240 b.i.d. | 200 b.i.d. (received clarithromycin (500 mg bid) first 5 days, followed by furazolidone (F) for the second 5 days. | 1000 b.i.d. | O | 20 b.i.d. | 10 | 106 | 82 | 98 | 88.7 | UBT | Lost (n=1) Side effect (n=1) No UBT (n=6) |
[30] |
PPI, proton pump inhibitor; PP, per protocol; q.i.d., four times daily; b.i.d., twice daily; q.i.d., four times daily; q.d. daily; ITT, intention to treat; BPC, bismuth potassium citrate; O, omeprazole; P, pantoprazole.
Table 2.
Yea r | City | Treatment Protocol | Treatment Success | Assays | Reasons for non-compliance | Ref | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bismuth (BPC) | Furazolidone | Tetracycline | PPI | Days | ITT | PP% | ||||||||
O/P | Dose | N | % | N | % | |||||||||
2009 | Rasht | 240 b.i.d | 200 b.i.d. | 500 b.i.d. | O | 20 b.i.d. | 7 | 61 | 71 | – | – | UBT | rare | [33] |
2005 | Tehran | 120 b.i.d | 100 b.i.d. | 500 b.i.d. | O | 20 b.i.d. | 14 | 76 | 68.4 | – | – | UBT | Poor Adherance | [35] |
2014 | Jahrom | 120 b.i.d | 100 q.i.d. | 250 q.i.d. | O | 20 b.i.d. | 14 | 55 | 94.5 | 55 | 94.5 | UBT | rare | [31] |
2001 | Tehran | 240 b.i.d | 200 b.i.d. | 500 b.i.d. | O | 20 once | 14 | 80 | 90 | 80 | 90 | UBT | rare | [27] |
2009 | Rasht | 240b.i.d | 200 b.i.d. | 500 b.i.d. | O | 20 b.i.d. | 14 | 74 | 65 | 69 | 69.7 | UBT | Side effect (n=5) | [33] |
PPI, proton pump inhibitor; PP, per protocol; q.i.d., four times daily; b.i.d., twice daily; q.i.d., four times daily; q.d. daily; ITT, intention to treat; BPC, bismuth potassium citrate; O, omeprazole; P, pantoprazole.
Table 1 (bismuth, furazolidone, amoxicillin, PPI quadruple therapies) presents studies which used furazolidone doses of 100 mg or 200 mg b.i.d. for 7 to 14 days. Fourteen day therapy with furazolidone 100 mg b.i.d (3 studies[21;28;40]). achieved relatively poor results with PP ranging from 56% to 85.7% (weighted mean for PP and ITT were 71% and 67%, respectively, Table 1). There were 4 studies [32;37;41;42] using a sequential therapy with furazolidone 200 mg b.i.d. given for the first week of a two week therapy. The weighted mean cure rates of these studies were 89 and 81% for PP and ITT, respectively. Only one 10 day regimen was studied and achieved cure rates of 86.6% and 83.7% for PP and ITT, respectively [38]. Fourteen day therapy (6 studies[21;24–26;29;43]) all with 200 mg b.i.d. furazolidone (Table 1b) did somewhat better with 3 of the studies [21;24;43] having PP cure rates of 90% or greater. The weighted mean cure rates for the six 14 day- studies[21;24–26;29;43] were 87% and 80%, PP and ITT, respectively.
Table 2 shows the 5 studies with bismuth, furazolidone, tetracycline, PPI quadruple therapy. Studies with furazolidone 200 mg b.i.d. for 7 day [33] or 100 mg b.i.d. for 14 days [35] produced poor results (eg, 71% [33] and 68.4% [35] ITT, respectively). One 14 day study [33] with 200 mg b.i.d. gave poor results (65% ITT, 69.7% PP) and one that gave omeprazole only once a day[27], surprisingly did better with 90% ITT and PP results. The best result was obtained with furazolidone 100 mg q.i.d. for 14 days [31] which achieved 94.5% ITT and PP results.
Table 3 shows 1 study (two trials) [30] with novel sequential therapies, where either 200 mg b.i.d metronidazole or clarithromycin was given for 5 days followed by 200 mg b.i.d. furazolidone for the second 5 days along with bismuth, the PPI, and 1000 mg amoxicillin for the full 10 days. These two trials had a PP cure rate of 91.3% and 88.7% respectively (Table-3). The problem with interpreting these results include the lack of susceptibility data for metronidazole and clarithromycin, which would likely influence the outcome to a great extent.
Discussion
Furazolidone is a monoamine oxidase inhibitor (MAO) which interacts with a number of other drugs and especially with commonly used foods such as soy sauce and aged cheese [6]. Successful ITT results require patients to be educated regarding food and drug avoidances. Most find that a description of the symptoms likely to occur is useful to prepare the patient and to encourage them to complete the therapy [44]. There has also been confusion in the literature based on some authors’ erroneous description of furazolidone as a human carcinogen [45]. The carcinogenicity of furazolidone was examined by the World Health Organization and and was listed as Class III (i.e., there was no evidence for its carcinogenicity in man) [6]. It should be noted, however, that one of the most commonly used antimicrobials for H. pylori, metronidazole, is classified as a Class I (definite) human carcinogen [6].
Successful H. pylori eradication has been defined as one that will reliably achieve an ITT cure rate of at least 90% and/or a 95% or greater PP cure rate in regimen-adherent patients with susceptible infections [46]. In Iran, H. pylori therapy consisting of omeprazole 20 mg, amoxicillin 1,000 mg, and bismuth citrate 240 mg with either 100 or 200 mg of furazolidone, all twice a day failed to reliably achieve this objective. Fourteen day full dose b.i.d. therapy provided ITT cure rates between 67% and 92% (weighted mean of 80%). In Iran, the dose of furazolidone is generally limited to a maximum of 200 mg b.i.d, because of the concern regarding the possible high rates of severe adverse drug reactions [25]. On the other hand, doses of less than 400 mg/day were locally considered ineffective for H. pylori eradication [21;21;47].
In this review, the best cure rate (i.e., 94.5%) for furazolidone quadruple therapy was achieved in a small study (55 subjects) using tetracycline and furazolidone 100 mg q.i.d. along with bismuth (q.i.d) and omeprazole twice daily [31]. Review of these studies helps provide a basis to develop a strategy to identify reliably effective furazolidone-bismuth containing regimens for Iran and possibly other countries where furazolidone is available.
Recommendations for future studies
The components of a successful H. pylori therapy include the different drugs, formulations, doses, frequency of administration, and duration of therapy. The list of drugs includes anti-secretory agents, bismuth, amoxicillin or tetracycline, and furazolidone. Studies from China showed that doses, dosing intervals and duration are all important [3]. In China the best results were achieved with furazolidone 100 mg t.i.d. for 14 days. In this review, 100 mg furazolidone q.i.d. was best, although it was reported by only one study and t.i.d. furazolidone therapy was not tested [31]. Future studies comparing lower individual furazolidone doses such as 100 mg t.i.d. vs. q.i.d. appear worthwhile.
Recent guidelines show improved cure rates with both standard triple therapy and bismuth quadruple therapy when using double dose PPI, (eg, 40 mg omeprazole or an equivalent b.i.d.) [48]. Most current studies from Iran used 20 mg of omeprazole b.i.d and it would be interesting to compare the effects of using higher doses of PPIs as well as those which are resistant to CYP2C19 metabolism (rabeprazole or esomeprazole). In other trials of bismuth quadruple therapies, bismuth dosing has most often ranged from 2 to 4 times daily [49]. Although it appears that the doses used here (240 mg of bismuth citrate b.i.d.) are most likely adequate, comparisons with more frequent administration should be considered.
Recent studies with amoxicillin-containing bismuth quadruple therapies have suggested increasing the dose of amoxicillin to 1 gram t.i.d., which has resulted in improved outcome [50;51]. Studies examining and comparing amoxicillin 1000 mg t.i.d. and lower doses such as 500 or 750 mg t.i.d. should also be carried out. Finally, when tetracycline is used, the dose has varied from 500 mg q.i.d. to 250 mg q.i.d.. Overall 500 mg b.i.d. appears to be successful, but it is interesting that the most successful trial in Iran used 250 mg q.i.d. [31]. Further examination of tetracycline dosing seems warranted. Overall, if a reduced dose of both furazolidone and tetracycline results in a reduction in side effects and/or improved regimen-adherence, they would be worth considering, provided the cure rates are not adversely affected.
Since resistance to amoxicillin, tetracycline, and furazolidone have been reported from Iran [17;18;52–55], one cannot assume that all infections are susceptible. Future studies should include collection and storage of biopsies for culture and susceptibility testing so that the results can be interpreted in relation to the susceptibility patterns. Gastric biopsies placed in transport media and stored at −70C remain viable indefinitely and thus allow susceptibility testing to be done when and where convenient [56]. Agar dilution methods are recommended as they are considered reliable and common standard worldwide.
The World Health Organization recently listed H. pylori among the high priority group of the infections, where resistance has become an issue [57]. Their publication was designed to guide research companies and scientists to develop new drugs, overcoming current anti-microbial resistance. Currently, resistance in H. pylori is still rare against furazolidone, amoxicillin, tetracycline, and rifabutin. While new drugs are being developed, it behooves us to learn to better use these drugs, which we have available.
Acknowledgments
The authors thank Dr. Farideh Siavoshi, Ph.D. for her many helpful comments and references.
Support: Dr. Graham is supported in part by the Office of Research and Development Medical Research Service Department of Veterans Affairs, Public Health Service grant DK56338 which funds the Texas Medical Center Digestive Diseases Center. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the VA or NIH.
Footnotes
Potential conflicts: Dr. Graham is a paid consultant for RedHill Biopharma regarding novel H. pylori therapies and for BioGaia regarding use of probiotics for H. pylori infections. Dr. Tansel declares no conflicts.
References
- 1.Zheng ZT, Wang YB. Treatment of peptic ulcer disease with furazolidone. J Gastroenterol Hepatol. 1992;7:533–537. doi: 10.1111/j.1440-1746.1992.tb01034.x. [DOI] [PubMed] [Google Scholar]
- 2.Borsch GM, Graham DY. Helicobacter pylori. In: Collen MJ, Benjamin SB, editors. Pharmacology of Peptic Ulcer Disease. Vol. 99. Berlin: Springer-Verlag; 1991. pp. 107–148. (Handbook of Experimental Pharmacology). [Google Scholar]
- 3.Lu H, Zhang W, Graham DY. Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China. Eur J Gastroenterol Hepatol. 2013;25:1134–1140. doi: 10.1097/MEG.0b013e3283633b57. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Liang X, Xu X, Zheng Q, Zhang W, et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol. 2013;11:802–807. doi: 10.1016/j.cgh.2013.01.008. [DOI] [PubMed] [Google Scholar]
- 5.Altamirano A, Bondani A. Adverse reactions to furazolidone and other drugs. A comparative review. Scand J Gastroenterol Suppl. 1989;169:70–80. doi: 10.3109/00365528909091336. [DOI] [PubMed] [Google Scholar]
- 6.Graham DY, Lu H. Furazolidone in Helicobacter pylori therapy: Misunderstood and often unfairly maligned drug told in a story of French bread. Saudi J Gastroenterol. 2012;18:1–2. doi: 10.4103/1319-3767.91724. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Zhang YX, Zhou LY, Song ZQ, Zhang JZ, He LH, Ding Y. Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing: a prospective serial study. World J Gastroenterol. 2015;21:2786–2792. doi: 10.3748/wjg.v21.i9.2786. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Su P, Li Y, Li H, Zhang J, Lin L, Wang Q, et al. Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China. Helicobacter. 2013;18:274–279. doi: 10.1111/hel.12046. [DOI] [PubMed] [Google Scholar]
- 9.Song Z, Zhou L, Xue Y, Bai P, Lin S, He L, et al. A study to explore HP antibiotic resistance and efficacy of eradication therapy in China (multi-center, nationa-wide, randomized, control study) Helicobacter. 2011;16(Suppl 1):117–118. [Google Scholar]
- 10.Mohammadi M, Doroud D, Mohajerani N, Massarrat S. Helicobacter pylori antibiotic resistance in Iran. World J Gastroenterol. 2005;11:6009–6013. doi: 10.3748/wjg.v11.i38.6009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Shokrzadeh L, Jafari F, Dabiri H, Baghaei K, et al. Antibiotic susceptibility profile of Helicobacter pylori isolated from the dyspepsia patients in Tehran, Iran. Saudi J Gastroenterol. 2011;17:261–264. doi: 10.4103/1319-3767.82581. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Siavoshi F, Safari F, Doratotaj D, Khatami GR, Fallahi GH, Mirnaseri MM. Antimicrobial resistance of Helicobacter pylori isolates from Iranian adults and children. Arch Iran Med. 2006;9:308–314. [PubMed] [Google Scholar]
- 13.Fakheri H, Bari Z, Aarabi M, Malekzadeh R. Helicobacter pylori eradication in West Asia: a review. World J Gastroenterol. 2014;20:10355–10367. doi: 10.3748/wjg.v20.i30.10355. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Safaralizadeh R, Siavoshi F, Malekzadeh R, Akbari MR, et al. Antimicrobial effectiveness of furazolidone against metronidazole-resistant strains of Helicobacter pylori. East Mediterr Health J. 2006;12:286–293. [PubMed] [Google Scholar]
- 15.Farshad S, Alborzi A, Japoni A, Ranjbar R, et al. Antimicrobial susceptibility of Helicobacter pylori strains isolated from patients in Shiraz, Southern Iran. World J Gastroenterol. 2010;16:5746–5751. doi: 10.3748/wjg.v16.i45.5746. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Khademi F, Faghri J, Poursina F, Esfahani BN, et al. Resistance pattern of Helicobacter pylori strains to clarithromycin, metronidazole, and amoxicillin in Isfahan, Iran. J Res Med Sci. 2013;18:1056–1060. [PMC free article] [PubMed] [Google Scholar]
- 17.Kohanteb J, Bazargani A, Saberi-Firoozi M, Mobasser A. Antimicrobial susceptibility testing of Helicobacter pylori to selected agents by agar dilution method in Shiraz-Iran. Indian J Med Microbiol. 2007;25:374–377. doi: 10.4103/0255-0857.37342. [DOI] [PubMed] [Google Scholar]
- 18.Milani M, Ghotaslou R, Akhi MT, Nahaei MR, et al. The status of antimicrobial resistance of Helicobacter pylori in Eastern Azerbaijan, Iran: comparative study according to demographics. J Infect Chemother. 2012;18:848–852. doi: 10.1007/s10156-012-0425-4. [DOI] [PubMed] [Google Scholar]
- 19.Malekzadeh R, Mohamadnejad M, Siavoshi F, Massarrat S. Treatment of Helicobacter pylori infection in Iran: low efficacy of recommended western regimens. Arch Iranian Med. 2004;7:1–8. [Google Scholar]
- 20.Hosseini V, Mokhtare M, Gholami M, Taghvaei T, et al. A Comparison between Moderate- and High-dose Furazolidone in Triple Regimens for Helicobacterpylori Eradication in Iran. Middle East J Dig Dis. 2014;6:195–202. [PMC free article] [PubMed] [Google Scholar]
- 21.Fakheri H, Merat S, Hosseini V, Malekzadeh R. Low dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2004;19:89–93. doi: 10.1046/j.1365-2036.2003.01822.x. [DOI] [PubMed] [Google Scholar]
- 22.Malekzadeh R, Masserat S, Saberi Firuzi M, Nasseri Moghaddam S, et al. Clinical guide to Helicobacter pylori infection of the stomach. Digestive Diseases Research Institute produced in cooperation with the Secretariat of the Research and Development of Policy of the University of Tehran University of Medical Sciences, Deputy of 1391 [Meeting Report] 2012 [Google Scholar]
- 23.Fakheri H, Malekzadeh R, Merat S, Khatibian M, et al. Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. Aliment Pharmacol Ther. 2001;15:411–416. doi: 10.1046/j.1365-2036.2001.00931.x. [DOI] [PubMed] [Google Scholar]
- 24.Khatibian M, Ajvadi Y, Nasseri-Moghaddam S, Ebrahimi-Dariani N, et al. Furazolidone-based, metronidazole-based, or a combination regimen for eradication of Helicobacter pylori in peptic ulcer disease. Arch Iran Med. 2007;10:161–167. [PubMed] [Google Scholar]
- 25.Daghaghzadeh H, Emami MH, Karimi S, Raeisi M. One-week versus two-week furazolidone-based quadruple therapy as the first-line treatment for Helicobacter pylori infection in Iran. J Gastroenterol Hepatol. 2007;22:1399–1403. doi: 10.1111/j.1440-1746.2007.05029.x. [DOI] [PubMed] [Google Scholar]
- 26.Ebrahimi-Dariani N, Mirmomen S, Mansour-Ghanaei F, Noormohammadpoor P, et al. The efficacy of furazolidone-based quadruple therapy for eradication of Helicobacter pylori infection in Iranian patients resistant to metronidazole-based quadruple therapy. Med Sci Monit. 2003;9:I105–I108. [PubMed] [Google Scholar]
- 27.Sotoudehmanesh R, Malekzadeh R, Vahedi H, Dariani NE, Asgari AA, Massarrat S. Second-line Helicobacter pylori eradication with a furazolidone-based regimen in patients who have failed a metronidazole-based regimen. Digestion. 2001;64:222–225. doi: 10.1159/000048865. [DOI] [PubMed] [Google Scholar]
- 28.Taghavi SA, Jafari A, Eshraghian A. Efficacy of a new therapeutic regimen versus two routinely prescribed treatments for eradication of Helicobacter pylori: a randomized, double-blind study of doxycycline, co-amoxiclav, and omeprazole in Iranian patients. Dig Dis Sci. 2009;54:599–603. doi: 10.1007/s10620-008-0374-z. [DOI] [PubMed] [Google Scholar]
- 29.Ghadir MR, Shafaghi A, Iranikhah A, Pakdin A, Joukar F, Mansour-Ghanaei F. Furazolidone, amoxicillin and omeprazole with or without bismuth for eradication of Helicobacter pylori in peptic ulcer disease. Turk J Gastroenterol. 2011;22:1–5. [PubMed] [Google Scholar]
- 30.Riahizadeh S, Malekzadeh R, Agah S, Zendehdel N, et al. Sequential metronidazole-furazolidone or clarithromycin-furazolidone compared to clarithromycin-based quadruple regimens for the eradication of Helicobacter pylori in peptic ulcer disease: a double-blind randomized controlled trial. Helicobacter. 2010;15:497–504. doi: 10.1111/j.1523-5378.2010.00798.x. [DOI] [PubMed] [Google Scholar]
- 31.Jahromi RR, Mirzaei J, Rajabi J, Shokouh SJH, Liaghat T. Furazolidone-based quadruple therapy for eradication of Helicobacter pylori infection in peptic ulcer disease. Arch Clin Infect Dis. 2014;9:e18549. [Google Scholar]
- 32.Fakheri HT, Fakhri M, Shahmohammadi S. Efficacy of short-duration Furazolidone in two different quadruple regimens for H. pylori eradication. Pak J Med Sci. 2011;27:887–891. [Google Scholar]
- 33.Mansour-Ghanaei F, Mashhour MY, Heidarzadeh A, Jafarshad R, et al. Helicobacter pylori ran away furazolidone-based quadruple therapy! Middle East Journal of Digestive Diseases (MEJDD) 2009;1:2–6. [Google Scholar]
- 34.Hasan SR, Vahid V, Reza M, Roham SR. Short-duration furazolidone therapy in combination with amoxicillin, bismuth subcitrate, and omeprazole for eradication of Helicobacter pylori. Saudi J Gastroenterol. 2010;16:14. doi: 10.4103/1319-3767.58762. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Amini M, Khedmat H, Yari F. Eradication rate of Helicobacter pylori in dyspeptic patients. Med Sci Monit. 2005;11:CR193–195. [PubMed] [Google Scholar]
- 36.Fakheri H, Bari Z, Sardarian H. A modified bismuth-containing quadruple therapy including a short course of furazolidone for Helicobacter pylori eradication after sequential therapy failure. Helicobacter. 2012;17:264–268. doi: 10.1111/j.1523-5378.2012.00946.x. [DOI] [PubMed] [Google Scholar]
- 37.Fakheri H, Taghvaei T, Hosseini V, Bari Z. A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: a randomized clinical trial. Helicobacter. 2012;17:43–48. doi: 10.1111/j.1523-5378.2011.00896.x. [DOI] [PubMed] [Google Scholar]
- 38.Mokhtare M, Hosseini V, Tirgar FH, Maleki I, et al. Comparison of quadruple and triple furazolidone containing regimens on eradication of Helicobacter pylori. Med J Islam Repub Iran. 2015;29:195. [PMC free article] [PubMed] [Google Scholar]
- 39.Rahmani A, Jafari A, Mabrokzadeh H, Asadollahi K. Comparison between the effectiveness of furazolidone and clarithromycin on eradication of Helicobacter pylori among patients with peptic ulcer. J Basic Res Med Sciences. 2015;2:45–50. [Google Scholar]
- 40.Bahari A, Nazam SK, Karimi M, Firouzeh K, Firouzi F. Comparing furazolidone and tetracycline in quadruple therapy for eradication of Helicobacter pylori in dyspeptic patients. Gastroenterology and Hepatology from Bed to Bench. 2009;1:39–43. [Google Scholar]
- 41.Hasan SR, Vahid V, Reza M, Roham SR. Short-duration furazolidone therapy in combination with amoxicillin, bismuth subcitrate, and omeprazole for eradication of Helicobacter pylori. Saudi J Gastroenterol. 2010;16:14. doi: 10.4103/1319-3767.58762. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Fakheri H, Bari Z, Sardarian H. A modified bismuth-containing quadruple therapy including a short course of furazolidone for Helicobacter pylori eradication after sequential therapy failure. Helicobacter. 2012;17:264–268. doi: 10.1111/j.1523-5378.2012.00946.x. [DOI] [PubMed] [Google Scholar]
- 43.Fakheri H, Malekzadeh R, Merat S, Khatibian M, et al. Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. Aliment Pharmacol Ther. 2001;15:411–416. doi: 10.1046/j.1365-2036.2001.00931.x. [DOI] [PubMed] [Google Scholar]
- 44.Graham DY, Mohammadi M. Synopsis of antibiotic treatment. In: Kim N, editor. Helicobacter pylori. Singapore: Springer Science+Business Media; 2016. pp. 417–426. [Google Scholar]
- 45.Zullo A, Ierardi E, Hassan C, De F V. Furazolidone-based therapies for Helicobacter pylori infection: A pooled-data analysis. Saudi J Gastroenterol. 2012;18:11–17. doi: 10.4103/1319-3767.91729. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Graham DY, Dore MP. Helicobacter pylori therapy: a paradigm shift. Expert Rev Anti Infect Ther. 2016;14:577–585. doi: 10.1080/14787210.2016.1178065. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Roghani HS, Massarrat S, Shirekhoda M, Butorab Z. Effect of different doses of furazolidone with amoxicillin and omeprazole on eradication of Helicobacter pylori. J Gastroenterol Hepatol. 2003;18:778–782. doi: 10.1046/j.1440-1746.2003.03058.x. [DOI] [PubMed] [Google Scholar]
- 48.Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2016;61:646–664. doi: 10.1136/gutjnl-2012-302084. [DOI] [PubMed] [Google Scholar]
- 49.Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65:870–878. doi: 10.1136/gutjnl-2015-311019. [DOI] [PubMed] [Google Scholar]
- 50.Chen Q, Zhang W, Fu Q, Liang X, Liu W, Xiao S, Lu H. Rescue therapy for Helicobacter pylori eradication: A randomized non-inferiority trial of amoxicillin or tetracycline in bismuth quadruple therapy. Am J Gastroenterol. 2016;111:1736–1742. doi: 10.1038/ajg.2016.443. [DOI] [PubMed] [Google Scholar]
- 51.Zhang W, Chen Q, Liang X, Liu W, Xiao S, Graham DY, et al. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut. 2015;64:1715–1720. doi: 10.1136/gutjnl-2015-309900. [DOI] [PubMed] [Google Scholar]
- 52.Fallahi GH, Maleknejad S. Helicobacter pylori culture and antimicrobial resistance in Iran. Indian J Pediatr. 2007;74:127–130. doi: 10.1007/s12098-007-0003-4. [DOI] [PubMed] [Google Scholar]
- 53.Maleknejad S, Mojtahedi A, Safaei-Asl A, Taghavi Z, Kazemnejad E. Primary antibiotic resistance to Helicobacter pylori strains isolated from children in Northern Iran: A single center study. Iran J Pediatr. 2015;25:e2661. doi: 10.5812/ijp.2661. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Talebi Bezmin AA, Mobarez AM, Taghvaei T, Wolfram L. Antibiotic resistance of Helicobacter pylori in Mazandaran, North of Iran. Helicobacter. 2010;15:505–509. doi: 10.1111/j.1523-5378.2010.00795.x. [DOI] [PubMed] [Google Scholar]
- 55.Siavoshi F, Saniee P, Latifi-Navid S, Massarrat S, Sheykholeslami A. Increase in resistance rates of H. pylori isolates to metronidazole and tetracycline–comparison of three 3-year studies. Arch Iran Med. 2010;13:177–187. [PubMed] [Google Scholar]
- 56.Han SW, Flamm R, Hachem CY, Kim HY, et al. Transport and storage of Helicobacter pylori from gastric mucosal biopsies and clinical isolates. Eur J Clin Microbiol Infect Dis. 1995;14:349–352. doi: 10.1007/BF02116531. [DOI] [PubMed] [Google Scholar]
- 57.Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. World Health Organization; 2017. [Google Scholar]